Pharmaceutical company AstraZeneca will resume some of its human trials of its COVID-19 vaccine after a brief hiatus due to a patient’s illness on Sunday.
AstraZeneca officials have said trials can resume in the UK after approval by the UK Medicines Health Regulatory Authority, the Financial Times reported Saturday.
The Anglo-Swedish company did not comment on the condition of the unhealthy patient that caused his trials to stop. AstraZeneca and Oxford’s statements also did not imply whether testing in other countries such as the United States, where dozens of sites are achieving human results. vaccine trials would be allowed to resume.
The only volunteer to become ill was one of 18,000 other people involved in the AstraZeneca COVID-19 “AZD1222” vaccine trials.
Although more than 1,000 patients in the trial experienced minor side effects such as chills and muscle pain, the volunteer who prompted the trials to discontinue the trials suffered a conceivable “serious adverse reaction. “
The participant, from the United Kingdom, allegedly had neurological symptoms indicating transverse myelitis, a rare inflammatory disorder of the spine.
An update on the participant’s condition in poor health or another diagnosis not included in AstraZeneca’s announcement to resume testing in the UK.
The AstraZeneca vaccine is being developed in collaboration with the University of Oxford and is one of nine international coronavirus vaccines that have or are about to start testing a large number of volunteers.
The company said it expects to have a COVID-19 vaccine until the end of the year. AstraZeneca is also in the US Operation Warp Speed program. But it’s not the first time To drive the implementation of a coronavirus vaccine. -test tests.
It and its content are provided “as is”.